Report # DEV-0723 019 documented a deviation for GMP lots GMP-™@, Gmp-®4 Gopwhere final product mycoplasma test results provided by contract testing lab were determined by the contract lab to be invalid.
Inspection Record
Duke University — FDA 483 Findings
Inspectors Team Lead · Sukhanya JayachandraThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
The inventory control of raw materials is deficient.
The existing alarm system and its implementation are deficient.
A means of assuring data protection has not been established for the following computerized system.
The environmental monitoring program is deficient in ensuring that the cleanrooms are operating in a state of environmental control.
The Quality Unit does not have adequate contro] over critical materials.
Performance qualification (PQ) of numerous critical equipment was not completed prior to conducting process performance qualification runs (November 16, 2018 — January 17, 2019) and aseptic processing runs (August 2018).
Corrective actions and preventive actions (CAPA) implemented are not always being documented per the CAPA SOP COMM-QA-076.
The Quality Unit oversight of batch record review is deficient.
Procedures and process contro] designed to prevent microbiological contamination of drug product are not established with appropriate acceptance criteria.
The current cleaning procedures used in the cleanroom have not been qualified.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
A record as of the US FDA document published on 2026-10-30. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.